Eli Lilly (NYSE: LLY), one of the U.S.’s foremost pharmaceutical giants, faced a sharp 8% drop in its stock price after reporting disappointing third-quarter results, erasing nearly 70billionfromitsmarketvalue.Thepharmaceuticalgiantmissedbothearningsandrevenueexpectations,promptingseveralanalyststolowertheirpricetargets.LLYfive−daystockpricechart.Source:FinboldAtthetimeofwriting,LLYstockisdownover8818. Sales miss sparks i ...